Abstract CD44 is a family of transmembrane glycoproteins that act mainly as a receptor for hyaluronan. It can also bind some other extracellular matrix ligands (chondroitin sulphate, heparan sulphate, fibronectin, serglycin, osteopontin) with lower affinity. CD44 is encoded by a single gene containing 20 exons, 10 of which (vl-vlO) are variant exons inserted by alternative splicing. The standard, ubiquitously expressed isoform of CD44, does not contain sequences encoded by these variant exons. Numerous variant isoforms of CD44 containing different combinations of exons vl-vlO inserted into the extracellular domain can be expressed in proliferating epithelial cells and activated lymphocytes. CD44 plays a significant role in lymphocyte homing. Both alternative splicing and glycosylation influence receptor function of the molecule, usually reducing its affinity to hyaluronan. The cytoplasmic domain of CD44 communicates with the cytoskeleton via ankyrin and proteins belonging to the ezrin-moesin-radixin family. Relatively little is known about the intracellular events following interactions of CD44 with its ligands. Some variant isoforms, especially those containing sequences encoded by v6-v1O, are overexpressed in both human and animal neoplasms. In a rat pancreatic adenocarcinoma model one of the variant CD44 isoforms was proved to be determinant in the metastatic process. For some human neoplasms (carcinomas of the digestive tract, non-Hodgkin's lymphomas, thyroid carcinomas, and others) correlations have been made between the particular pattern of CD44 variants produced by neoplastic cells and clinicopathological parameters of tumours, such as grade, stage, presence of metastases, and survival. In vitro studies indicate that modifications of CD44 expression result in different ligand recognition and influence cell motility, invasive properties, and metastatic potential of experimental tumours. Investigation of CD44 neoexpression can be useful both in early cancer diagnosis and in predicting tumour behaviour. It can also contribute to better understanding of molecular mechanisms leading to neoplastic transformation.
affinity. CD44 is encoded by a single gene containing 20 exons, 10 of which (vl-vlO) are variant exons inserted by alternative splicing. The standard, ubiquitously expressed isoform of CD44, does not contain sequences encoded by these variant exons. Numerous variant isoforms of CD44 containing different combinations of exons vl-vlO inserted into the extracellular domain can be expressed in proliferating epithelial cells and activated lymphocytes. CD44 plays a significant role in lymphocyte homing. Both alternative splicing and glycosylation influence receptor function of the molecule, usually reducing its affinity to hyaluronan. The cytoplasmic domain of CD44 communicates with the cytoskeleton via ankyrin and proteins belonging to the ezrin-moesin-radixin family. Relatively little is known about the intracellular events following interactions of CD44 with its ligands. Some variant isoforms, especially those containing sequences encoded by v6-v1O, are overexpressed in both human and animal neoplasms. In a rat pancreatic adenocarcinoma model one of the variant CD44 isoforms was proved to be determinant in the metastatic process. For some human neoplasms (carcinomas of the digestive tract, non-Hodgkin's lymphomas, thyroid carcinomas, and others) correlations have been made between the particular pattern of CD44 variants produced by neoplastic cells and clinicopathological parameters of tumours, such as grade, stage, presence of metastases, and survival. In vitro studies indicate that modifications of CD44 expression result in different ligand recognition and influence cell motility, invasive properties, and metastatic potential of experimental tumours. Investigation of CD44 neoexpression can be useful both in early cancer diagnosis and in predicting tumour behaviour. It can also contribute to better understanding of molecular mechanisms leading to neoplastic transformation. Terminology CD44 is a family of glycoprotein molecules, which received its name during the Third International Workshop on Leukocyte Differentiation Antigens.' This nondescriptive term has replaced names used previously, including: lymphocyte homing receptor (gp0Hermes), phagocytic glycoprotein (Pgp-i), extracellular matrix receptor III (ECMRIII), and hyaluronate receptors (H-CAM) and HUTCH-1. CD44 was described first in the early 1980s, based on the reactivity of an antibody called F 10.44.2."2 Because the separately described and named molecules with diverse functions were found to be the product of one gene, the interest in CD44 increased rapidly, resulting in over 800 publications in the past five years.
Genomic organisation and protein structure CD44 is the product of a single gene, located on the short arm of human chromosome i1.5
Genomic DNA studies have documented that CD44 is encoded by at least 20 exons. The first five (sl-s5) as well as exons 16 to 20 (s6-s10) are almost invariably expressed by a large number of non-epithelial cells, including those which are haematopoietic; their product is referred to as the "standard" or "haematopoietic" form of CD44 ( Unlike the mouse CD44 gene, the human exon vl contains a stop codon at the 17th amino acid residue and probably does not give rise to a protein product.8 There is no evidence that human CD44 isoforms contain the vl sequence. Human genomic vl was discovered only after finding the homologous murine exon, therefore, it is sometimes designated as exon 5a or 6a, and subsequent exons receive the numbers from 6 to 19 or from 7 to 20, which can lead to some terminological confusion. 9 Similarly, there is no widely accepted terminology for the large number of resulting isoforms described, the only exception being that containing the product of exons v8-vlO, known as an "epithelial" variant (CD44E). However, even this isoform (CD44v48-1 0) has been called "CD44R1" by another group.'0 The largest human isoform, containing the insert encoded by all alternatively spliced exons from v2 to vlO was called "epican"." The number of isoforms documented so far approaches 100; theoretically there could be more than 1000 combinations.
The standard form of human CD44 is composed of 361 amino acids (37) (38) (39) (40) (41) (42) The B(X7)B motifs, located on the CD44 extracellular domain are essential, but not sufficient for optimal hyaluronan binding. It is also uncertain which CD44 isoform is involved, its post-translational modifications, and cellular context. The standard form of CD44 binds hyaluronan, whereas the ligand affinity of some variant isoforms, especially the "epithelial" one (CD44E) is much lower.24 46 It is presently unclear, why the insertion of the additional amino acids encoded by variant exons in a location remote from the hyaluronan binding sites affects the CD44-hyaluronan interaction. An important issue is to define the role played by variant CD44 isoforms in the attachment to hyaluronan. Studies addressing this issue have led to different conclusions-for example, the murine homologue of human CD44E and other heavier murine isoforms do bind to the ligand when transfected into the AKR1 lymphoma cells. 47 In addition, the CD44R1 isoform, when expressed in COS7 (SV40 transformed simian fibroblastoid cell line) or TILl (murine lymphoma) cells can bind hyaluronan.49 4 The CD44R1 isoform was regarded as similar but not identical to CD44E, but recently it was acknowledged that the amino acid composition of these two CD44 variants is the same (A Aruffo; personal communication). Whatever variant exon is spliced in CD44 transcripts, post-transcriptional modifications can still account for further changes in hyaluronan binding.
Various sugar moieties carried by CD44 modify its capacity to bind hyaluronan, probably by altering the folding or charge of the receptor molecule. 0-glycosylation and to a lesser extent N-glycosylation of the standard form of CD44 are necessary for transfected murine T lymphoma cells to bind to hyaluronan. 50 Interestingly, glycosylation of some of the variant domains of CD44 has the opposite effect.2 Thus variable glycosylation of the CD44 molecule, particularly its "epithelial" variant, can serve as a mechanism regulating lectin function of this glycoprotein parallel to alternative splicing. Similarly, the attachment of chondroitin sulphate or heparan sulphate, both negatively charged molecules, to the v3 encoded region of CD44 can have an adverse effect on hyaluronan binding. '7 Binding of CD44 positive cells to hyaluronan and their tumorigenesis potential also depend on whether CD44 remains attached to the plasma membrane or is shed in the extracellular space.5' Variant CD44 isoforms containing sequences encoded by v7-v 10 shed quite easily into the extracellular space, probably as a result of proteolytic cleavage of CD44 at the junction between the transmembrane and cytoplasmic domains. The released fragments block CD44 dependent tumour formation, which relies on adhesion of neoplastic cells to hyaluronan. In contrast, the standard CD44 isoform does not shed easily, promoting local tumour growth on subcutaneous injection into nude mice. Cells transfected with isoforms containing products of v3, which completely fail to bind hyaluronan and do not release CD44, are the most efficient in forming bone marrow metastases after intravenous injection. This leads to the suggestion that the extensive glycosylation of the v3 coded region has several corollaries: abrogation of hyaluronan binding, specific protection from proteolysis, and promotion of unique metastatic properties, possibly by trapping growth factors.5'
The cytoplasmic domain is essential for binding to soluble or immobilised hyaluronan and for hyaluronan-CD44 mediated motility. This process involves clustering of CD44 molecules at the surface of the cell. 52 Alterations in hyaluronan binding also relate to changes in the number of CD44 molecules expressed on the cell membrane. Activation of lymphocytes by phorbol esters increases the expression of the CD44 standard isoform and results in increased binding to hyaluronan."
Finally, the affinity of CD44 for hyaluronan depends on the size of the ligand molecule. Hyaluronan has no constant molecular mass in vivo and, generally, the longer the polymer chain the stronger the CD44 affinity for it. The minimal hyaluronan chain recognised by CD44 is six sugar residues in length. 9 Binding to hyaluronan is unlikely to be the only functional consequence of CD44 expression. It is conceivable that associated events are related to it, including hyaluronan degradation, cell motility, and intracellular signalling. Hyaluronan is degraded mostly in lymph nodes and to a lesser extent in the liver, spleen, kidneys, and lungs. To date, hyaluronan remains the only component to which CD44 binds specifically. Cell binding to collagen type I, laminin, and fibronectin are also CD44 dependent, but are weaker and rely on the presence of linked chondroitin sulphate chains.59 These interactions can also be mediated by CD44 isoforms containing products of variant exons, as some colonic carcinoma cell lines expressing CD44E show binding to type IV collagen and laminin that can be blocked by anti-CD44 antibodies. 60 In addition, CD44 negative murine lymphoma cells TILl transduced with CD44R1 (an isoform containing the product of exon v1O with the chondroitin sulphate chain attachment site) undergo spontaneous homotypic aggregation, probably mediated by the mutual recognition of CD44R1 molecules and chondroitin sulphate chains. 49 Recently, serglycin (the sulphated proteoglycan of leucocyte secretory granules) was identified as another ligand for CD44. Serglycin can be exocytosed and interacts with CD44 on cell membrane leading to activation of lymphocytes. Again, the binding to CD44 is dependent on the chondroitin sulphate chains carried by the serglycin molecule.6' Heparan sulphate, attached to the region encoded by exon v3, contributes to another function of CD44 heavy weight isoforms, that is the binding of growth factors, possibly presenting them at sites of inflammatory reactions. Heparin binding epithelial growth factor (HB-EGF) and basic fibroblast growth factor (b-FGF), which are determinants of angiogenesis, belong to those so far identified.62 According to a recent report, osteopontin, which is a ubiquitous extracellular matrix glycoprotein, may be another ligand for CD44.4 Osteopontin was originally described as a protein involved in bone apatite crystal formation, but it is also produced by a number of epithelial cells, vascular smooth muscle cells, and lymphocytes. Osteopontin 
LYMPHOMAS
The numerous attempts that have been made for a consensus classification of non-Hodgkin's lymphomas reflect the frequent unpredictability in behaviour and insufficient correlation between morphological and clinical features of these neoplasms. Consequently, active searches are being pursued to identify new markers enabling more accurate classification and prognosis. The role of CD44 in lymphocyte homing together with the transient upregulation of large CD44 isoforms in activated lymphoid cells provided a rationale for assessing its potential participation in lymphoma progression. As a basis of this study, it was noticed that when the Namalwa lymphoma cell line was transfected with standard CD44, its metastatic potential was greatly enhanced. 84 Nodular lymphomas, which are relatively indolent, are typically CD44 negative, in contrast to the usually more aggressive diffuse lymphomas which are strongly CD44 positive. 85 Overall, CD44 expression correlates with poor prognosis in gastrointestinal lymphoma.86 A substantial fraction of gastrointestinal lymphomas reported in this study (52%) showed no expression of CD44 and were characterised by a more favourable clinical outcome. More detailed data can be obtained using reagents that are specific for alternatively spliced exons present in CD44 variant isoforms. The CD44 transcripts found in diffuse large cell lymphomas contain alternative splicing products which are not expressed in normal resting lymphocytes and resemble those found in activated B cells.87 Overexpression of isoforms containing protein product of exons v3, v6, and v9 (but not v4) was observed in high grade lymphomas, as opposed to the low grade lymphoid neoplasms.7 88 Additionally, multivariate analysis of morphological, clinical and molecular parameters obtained in a large cohort of patients with high grade non-Hodgkin's lymphoma demonstrated that the presence of CD44 v6 product was an independent prognostic factor.89 Interestingly, CD44 negative human Burkitt's lymphoma cells transfected with large variant CD44 isoforms showed weaker adhesion to hyaluronate and increased aggressiveness, as documented by in vivo tests.5' The causal relationship between these two phenomena has not been proved but it is tempting to speculate that the decreased affinity to extracellular matrix can facilitate mobilisation of lymphoma cells and promote their spread via blood and lymphatic vasculature.
However, at least in animal models, determinant factors other than CD44 relate to the aggressiveness of lymphoma. For instance, the MDAY-D2 murine lymphoma line in which CD44 is inactivated retains both its local invasiveness and metastatic potential, despite a complete loss of hyaluronan binding ability.90
The level of soluble standard form and v6 containing CD44 isoforms can be measured in the blood of lymphoma patients and behaves as a useful marker in monitoring the effects of therapy. 9' In contrast to non-Hodgkin's lymphomas, the role of CD44 and its variants in the biology of Hodgkin's disease is not understood. (fig 2) .
Immunohistochemical investigations with antibodies specific for discrete variant exon products have documented the pattern of CD44 isoform expression in colon cancer.97 98 The isoforms containing sequences encoded by alternatively spliced exons v5 and v6 can be seen in lesions as early as small adenomas (diameter < 1 cm). In particular, v5 is strongly positive in almost all adenomas, whereas v6 lags behind, being positive in 17% of early adenomatous lesions, reaching 82% positivity in advanced carcinomas (Dukes' C or D) ( fig  3) . In contrast to v5, v6 expression correlates positively with the grade of dysplasia in premalignant tumours. Overall, the acquisition of exon v5 expression occurs early in colorectal tumour development. CD44 isoforms containing v6 appear later, characterise a large subset of neoplasms, probably correspond chronologically to the p53 mutations, and lead to a growth advantage of positive tumour cell subclones.98 Antibodies against epitopes encoded by exon v7 and v8-v10 react strongly with neoplastic cells of adenomas and carcino- investigations open perspectives of a new promising colon cancer screening method since intron v4-v5 could be detected in 73% of stool specimens from cancer patients."6 Analysis of genomic DNA clones excludes mutations at the exon-intron boundaries as a cause of splicing defects and the mechanism of this puzzling anomaly of mRNA processing remains unexplained."4
The concentration of soluble CD44 increases in the serum of colorectal cancer patients, usually exceeding the normal value by a factor of 10 and returning to normal after curative resection.36 Thus, it can be assayed as a sensitive indicator of tumour burden useful in monitoring the effect of therapy, rather than in initial diagnosis. There is no indication, however, that serum CD44 could be more sensitive or more specific than serum carcinoembryonic antigen.
It is relevant to question whether a specific CD44 isoform has a promoting or a suppressing effect on colon cancer, an issue that has been addressed with recent experiments using nude mice xenotransplanted with manipulated cell lines.'0917" Expression of standard CD44 in colonic cancer cells that do not normally express it, led to a markedly diminished tumorigenicity; this reduction required an intact cytoplasmic domain. At the same time the cells adhered more strongly to hyaluronan, a function typically associated with the standard isoform of CD44. Taken together, these observations suggest that the standard isoform of CD44 might have tumour suppressor properties. This suggestion cannot be generalised, however, as different human tumours have a different biology in this respect. Indeed, comparable experiments performed with a melanoma cell line showed that the standard isoform of CD44 promoted tumorigenicity in non-epithelial neoplasms.95 The exact mechanisms whereby CD44 isoforms containing alternatively spliced exons increase the malignant potential of colonic carcinoma cells is unclear. It is possible that blood group H antigen, which can form a complex with the v6 exon of CD44, participates in tumorigenicity. In a rat colonic adenocarcinoma cell line the same antigen was responsible for high tumorigenicity, whereas inhibition of fucosylation not only abrogated its presentation but also markedly reduced tumour growth in syngeneic rats. 8 Thus, once again, the way CD44 radically modifies cell behaviour seems to be dependent on the unique pattern of glycosylation, itself determined by alternative splicing. It has been established that the expression of this carbohydrate antigen correlates negatively with the prognosis of human colorectal cancer."8 In an investigation of lung adenocarcinoma using an antibody that does not distinguish standard from variant CD44 isoforms, a poor prognosis was associated with decreased CD44 expression.136 Furthermore, in nine cases of small cell carcinoma of the lung, no CD44 expression was found, which contrasts with the positive reaction of most non-small cell primary lung carcinomas. '34 The results of these studies contribute to the complexity of interrelations between CD44 expression and behaviour of neoplastic cells. They contrast with most of the analogous research on gastrointestinal tumours, but seem to support the experimental data showing that reintroduction of CD44H into colonic carcinoma cells reduces their tumorigenicity.'09
In addition to carcinomas characterised by either positive or negative associations between clinical outcome and expression of CD44, there are also some carcinomas in which complete data on prognostic significance (as defined by overall survival and recurrence free survival) are unknown. Nevertheless, in these tumours, CD44 expression has been compared with specific pathological and clinical features. For instance, in ovarian serous carcinoma there was a link between the CD44 on the surface of cancer cells and the way in which the tumour spread in the peritoneal cavity. ' 
